Turning to PrEP for Prevention
February saw a possible turning point in the prevention of HIV, when Health Canada approved Truvada...
Learn MoreApril 7, 2016
Postdoc Spotlight: Dr. Nathan Lachowsky
“Young guys today didn’t live through the AIDS crisis,” says CTN postdoc Nathan Lachowsky in...
Learn More
Seeking a Reprieve for Heart Disease: CTN Partners with the ACTG
The REPRIEVE trial (A5332, CTN 293 – Randomized Trial to Prevent Vascular Events in HIV)...
Learn More
Postdoc Spotlight: Dr. Sarah Khan
HIV can be transmitted through breast milk, yet the risk of transmission is not well...
Learn More
Treatment Access Issues Dominate HIV/Viral Hepatitis Co-infection Meeting
Treatment access issues related to hepatitis C virus (HCV) infection and HIV-HCV co-infection dominated much...
Learn More
Experts meet in Vancouver to call for universal access to hepatitis C treatment
On Friday, July 17 and Saturday, July 18 the 2nd International HIV/Viral Hepatitis Co-Infection Meeting brought together...
Learn More
CTN Community Advisory Committee – Looking Back
In 1993 the formation of a community advisory committee was groundbreaking. Over the past 25...
Learn More
The CTN Marks 25 Years of Excellence
For the last 25 years the CTN has played a central role in driving Canada’s...
Learn More
ANRS IPERGAY Study (CTN 268) Update
The results of Phase I of the ANRS IPERGAY trial (CTN 268) are very promising,...
Learn More
TriiAdd study looks to improve adherence with a single pill per day
The TriiAdd study (CTN 286) will test to see if using a new single tablet...
Learn More
A breakthrough in HIV prevention
Early data from the CTN 268 – ANRS IPERGAY trial validates ‘on demand’ pre-exposure prophylaxis...
Learn More